Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Rosales-Rodríguez B, Núñez-Enríquez JC, Mejía-Aranguré JM, Rosas-Vargas H. Prognostic Impact of Somatic Copy Number Alterations in Childhood B-Lineage Acute Lymphoblastic Leukemia. Curr Oncol Rep 2020;23:2. [PMID: 33190177 DOI: 10.1007/s11912-020-00998-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/05/2020] [Indexed: 12/21/2022]

For:	Rosales-Rodríguez B, Núñez-Enríquez JC, Mejía-Aranguré JM, Rosas-Vargas H. Prognostic Impact of Somatic Copy Number Alterations in Childhood B-Lineage Acute Lymphoblastic Leukemia. Curr Oncol Rep 2020;23:2. [PMID: 33190177 DOI: 10.1007/s11912-020-00998-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/05/2020] [Indexed: 12/21/2022]

Number

Cited by Other Article(s)

Risinskaya N, Kozhevnikova Y, Gavrilina O, Chabaeva J, Kotova E, Yushkova A, Isinova G, Zarubina K, Obukhova T, Kulikov S, Julhakyan H, Sudarikov A, Parovichnikova E. Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL. Genes (Basel) 2022;13:genes13030398. [PMID: 35327952 PMCID: PMC8952291 DOI: 10.3390/genes13030398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/16/2022] [Accepted: 02/21/2022] [Indexed: 11/29/2022] Open

Affiliation(s)

Natalya Risinskaya National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Yana Kozhevnikova School of Medicine, Lomonosov Moscow State University, 27-1, Lomonosovsky Prospect, 119991 Moscow, Russia;
Olga Gavrilina National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Julia Chabaeva National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Ekaterina Kotova National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Anna Yushkova National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Galina Isinova National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Ksenija Zarubina National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Tatiana Obukhova National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Sergey Kulikov National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Hunan Julhakyan National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
Andrey Sudarikov National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.) Correspondence:
Elena Parovichnikova National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)

Collapse

Ampatzidou M, Florentin L, Papadakis V, Paterakis G, Tzanoudaki M, Bouzarelou D, Papadhimitriou SI, Polychronopoulou S. Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols. Cancers (Basel) 2021;13:cancers13133289. [PMID: 34209196 PMCID: PMC8268490 DOI: 10.3390/cancers13133289] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/25/2021] [Accepted: 06/25/2021] [Indexed: 01/03/2023] Open

Abstract

Simple Summary

Recent advances in genomic analyses of acute lymphoblastic leukemia (ALL) have identified novel prognostic markers associated with patient outcome. In this frame, copy number alterations (CNAs) are constantly gaining relevance as potential risk stratification markers. Herein, we present our data of a proposed CNA-profile risk-index applied on a Greek ALLIC-BFM cohort. The results of our study demonstrate that EFS for GR(good-risk)-CNA-profile patients was 96.0% versus 57.6% of PR(poor-risk)-CNA-profile ones (p < 0.001) in the whole cohort. EFS within the IR-group for the GR-CNA vs. PR-CNA subgroups was 100.0% vs. 60.0% (p < 0.001), and within the HR-group, 88.2% vs. 55.6% (p = 0.047), respectively. The above results indicate that the application of the proposed CNA-profile classifier is feasible in BFM-based protocols, adding prognostic value to the existing prognostic markers and successfully stratifying patients within prognostic subgroups. This novel genomic risk index can be incorporated in future risk-stratification algorithms, further refining MRD-based stratification and possibly reassigning optimal treatment strategies.

Abstract

We present our data of a novel proposed CNA-profile risk-index, applied on a Greek ALLIC-BFM-treated cohort, aiming at further refining genomic risk-stratification. Eighty-five of 227 consecutively treated ALL patients were analyzed for the copy-number-status of eight genes (IKZF1/CDKN2A/2B/PAR1/BTG1/EBF1/PAX5/ETV6/RB1). Using the MLPA-assay, patients were stratified as: (1) Good-risk(GR)-CNA-profile (n = 51), with no deletion of IKZF1/CDKN2A/B/PAR1/BTG1/EBF1/PAX5/ETV6/RB1 or isolated deletions of ETV6/PAX5/BTG1 or ETV6 deletions with a single additional deletion of BTG1/PAX5/CDKN2A/B. (2) Poor-risk(PR)-CNA-profile (n = 34), with any deletion of ΙΚΖF1/PAR1/EBF1/RB1 or any other CNA. With a median follow-up time of 49.9 months, EFS for GR-CNA-profile and PR-CNA-profile patients was 96.0% vs. 57.6% (p < 0.001). For IR-group and HR-group patients, EFS for the GR-CNA/PR-CNA subgroups was 100.0% vs. 60.0% (p < 0.001) and 88.2% vs. 55.6% (p = 0.047), respectively. Among FC-MRD_d15 + patients (MRD_d15 ≥ 10⁻⁴), EFS rates were 95.3% vs. 51.7% for GR-CNA/PR-CNA subjects (p < 0.001). Similarly, among FC-MRD_d33 + patients (MRD_d33 ≥ 10⁻⁴), EFS was 92.9% vs. 27.3% (p < 0.001) and for patients FC-MRD_d33 − (MRD_d33 < 10⁻⁴), EFS was 97.2% vs. 72.7% (p = 0.004), for GR-CNA/PR-CNA patients, respectively. In a multivariate analysis, the CNA-profile was the most important outcome predictor. In conclusion, the CNA-profile can establish a new genomic risk-index, identifying a distinct subgroup with increased relapse risk among the IR-group, as well as a subgroup of patients with superior prognosis among HR-patients. The CNA-profile is feasible in BFM-based protocols, further refining MRD-based risk-stratification.

Collapse